Creatinol-O-Phosphate Powder Crystals CAS 6903-79-3 Phospholipid Compound Enhance muscular endurance, delay fatigue, and facilitate recovery

Uses and Applications

1. Research and Pharmaceutical

COP continues to be used in biochemical research and as a reference standard. It has been investigated for potential applications in:

• Cardiovascular health (ischemic heart disease, arrhythmias)

• Rheumatoid arthritis and other inflammatory conditions (under investigation)

• Diabetic retinopathy (under investigation)

2. Sports Nutrition and Dietary Supplements

In the supplement industry, COP is marketed as an ergogenic aid for athletes and individuals engaged in intense physical training. Purported benefits include:

• Enhanced muscle endurance and contractility

• Delayed onset of muscle fatigue

• Improved recovery post-exercise

• Reduced muscle damage during high-intensity workouts

These claims are based primarily on theoretical mechanisms and older injection studies, not on modern oral supplementation trials.

3. Emerging Applications

Recent research has identified novel applications for COP. A 2024 study demonstrated its use as an interface modification material in perovskite solar cells, where it passivated surface defects and improved power conversion efficiency to 24.45%, also enhancing device stability. This highlights the compound's potential in materials science beyond biomedical applications.

Dosage and Administration

As there are no established guidelines for oral supplementation, typical recommendations are based on anecdotal sources and historical injection data:

Note: Due to the lack of oral bioavailability data, these dosages are not evidence-based. Anyone considering COP supplementation should consult a healthcare professional.

Safety and Side Effects

Reported Side Effects

• Mild: Gastrointestinal discomfort (with excessive oral doses)

• Rare: Dizziness or headaches

• With IV administration (historical): No significant toxicity observed at doses up to 3g; some reports noted increased urinary phosphorus and mild diuresis

Safety Considerations

• Pregnancy and Nursing: No safety data available; avoid use.

• Heart Conditions: Individuals with heart conditions should consult a healthcare provider before use.

• Regulatory Status:

  • United States: Legal as a dietary supplement ingredient.

  • European Union: Permitted within safety regulations.

  • Canada: Permitted under natural health product guidelines.

Important Limitations

• No long-term safety studies are available.

• No modern clinical trials have evaluated oral COP.

• The compound is considered a research chemical and should not be used for therapeutic purposes without professional guidance.

Comparison with Creatine Monohydrate

For practical purposes, COP should be viewed as a completely different molecule from creatine, with no proven equivalence in effect